Clinical trial NCT05838846: Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery
Official title: Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Mitral Valve Replacement
Pulmonary Hypertension
Inhaled Milrinone
Intravenous Milrinone
Keywords: Milrinone
Pulmonary Hypertension
Lead sponsor: Menoufia University
Sponsor class: OTHER
First posted: 2023-05-03
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This prospective open-label randomized study aims to compare the effect of inhaled versus intravenous milrinone on the pulmonary vascular resistance in patients undergoing mitral valve replacement surgery.

The primary outcome is to determine change in pulmonary artery pressure. The secondary outcomes include,

* Incidence of systemic hypotension.
* Hemodynamic affection and need of vasopressors and inotropes.
* Change in pulmonary vascular resistance versus systemic vascular resistance.
* Right ventricular function.
* Duration of mechanical ventilation.
* Need for mechanical circulatory support devices.
* Urine output
* Length of intensive care (ICU) in stay.

As the investigators hypothesize that inhaled milrinone has a selective pulmonary vasodilator effect devoid of the systemic hypotension with the intravenous administration.

Detailed description: All patients underwent standard preoperative cardiac surgery assessment. Premedication included bromazepam and ranitidine, given the night before and 2 hours prior to arrival to OT. On arrival, IV access and arterial cannula were inserted under local anesthesia, along with routine monitoring electrocardiogram (ECG), pulse oximetery (SpO2), and IBP.

Anesthesia was induced with midazolam, fentanyl, and cis-atracurium. After tracheal intubation, ultrasound (US) guided- central venous catheter (CVC) was inserted and TEE also applied and then anesthesia maintained with morphine, cis-atracurium infusions, and sevoflurane. Mechanical ventilation was set to maintain end-tidal carbon dioxide (etco2) in the range of 30-40 mmHg using lung protective ventilation strategies.

During CPB, flow of 2.2 L.min-1.m-2, a custodiol cardioplegia was given, temperature kept at 28-32℃ and anesthesia maintained by sevoflurane- through a vaporizer mounted on CPB machine-.

A senior consultant certified cardiac anesthetist conducted a baseline TEE using Philips EPIQ CVxi echocardiography machine. Baseline measures included left ventricular ejection fraction (LVEF), and RV function represented by tricuspid annulus plane systolic excursion (TAPSE), fractional area changes (FAC), and right ventricular systolic pressure (RVSP) by doppler also, PVR and systemic vascular resistance (SVR) was calculated, plus patients hemodynamics (mean arterial blood pressure (MAP), heart rate (HR)), all measures were recorded.

Eligibility criteria: Inclusion Criteria:

* Severe mitral regurgitation and moderate or severe pulmonary hypertension
* Scheduled for mitral valve replacement surgery

  # Criteria of severe mitral regurgitation:
* Central jet MR \>40% LA or holosystolic eccentric jet MR
* Vena contracta ≥ 0.7 cm
* Regurgitant volume ≥60 ml
* Regurgitant fraction ≥50%
* EROA ≥0.40 cm2

  # Criteria of moderate and severe pulmonary hypertension:
* Moderate pulmonary hypertension; mean pulmonary artery pressure \> 41 mmHg while, severe pulmonary hypertension; mean pulmonary artery pressure \> 55 mmHg
* Mean pulmonary artery pressure \> 40% of mean systemic blood pressure.
* Mean pulmonary artery pressure approximated from estimated systolic pulmonary artery pressure as following; mPAP= (estimated sPAP X 0.61) ± 2

Exclusion Criteria:

* Patients with aortic valvular lesions or pulmonary stenosis.
* Hemodynamic instability in the preoperative time (defined as acute requirement for vasoactive support or mechanical device).
* Contraindication to transesophageal echocardiography; esophageal stricture, tumor or diverticulum or active upper gastrointestinal bleeding
* Patients with hepatic or renal dysfunction.
* Patients with coagulopathy.
* Emergency surgeries.

Primary outcomes:
measure: Change in pulmonary artery pressure
timeFrame: Intraoperative
Secondary outcomes:
measure: Incidence of systemic hypotension
timeFrame: Intraoperative
measure: Hemodynamic affection and need of vasopressors and inotropes.
timeFrame: Intraoperative
measure: Pulmonary vascular resistance versus systemic vascular resistance
timeFrame: Intraoperative
measure: Right ventricular function
timeFrame: Intraoperative
measure: Duration of mechanical ventilation
timeFrame: Postoperative in ICU (up to 24 hours)
measure: Need for mechanical circulatory support devices
timeFrame: Intraoperative
measure: Urine output
timeFrame: Intraoperative
Other outcomes:
Locations:
city: Shibīn Al Kawm
country: Egypt
facility: Menoufia University Hospitals
state: Menoufia
Study officials:
affiliation: Faculty of Medicine - Menoufia University
name: Ghada A Hassan, Professor
role: STUDY_CHAIR
affiliation: Faculty of Medicine - Menoufia University
name: Mohamed A Salem, A. Professor
role: STUDY_CHAIR
affiliation: Faculty of Medicine - Menoufia University
name: Khaled M Gaballah, A. Professor
role: STUDY_CHAIR
affiliation: Faculty of Medicine - Ain Shams University
name: Mohammed O El Gouhary, Lecturer
role: STUDY_DIRECTOR
References: